We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Antibody Fragments Used in Pre-Clinical Pancreatic Cancer Imaging

By HospiMedica International staff writers
Posted on 11 Oct 2016
Researchers have shown that certain antibody fragments can be coupled with Zirconium, a Copper-based PET imaging agent, and a fluorescent imaging agent without impacting immunoreactivity, to target bladder and pancreatic cancer.

The research results indicated that rapid immunoPET (Positron Emission Tomography) or immunofluorescent imaging could be used to provide imaging results within one day, faster than other current methods.

The researchers from the Memorial Sloan Kettering Cancer Center (MSK; New York, NY, USA) produced the F(ab')2 antibody fragments from MabVax Therapeutics’ (San Diego, CA, USA) HuMab-5B1 antibodies for use as a PET imaging agent, and as a radio-immunotherapy agent. More...
MabVax Therapeutics specializes in developing and producing antibody-based clinical-stage oncology drugs.

David Hansen, CEO of MabVax Therapeutics, said, "We are grateful to Jason S. Lewis, PhD and his team for their continued pioneering work using the HuMab-5B1 platform. They are taking important steps in expanding the clinical utility of our HuMab-5B1 antibody, including (1) demonstrating that smaller fragments of our full-length antibody could provide significant advantages in speeding tumor imaging, (2) demonstrating the utility of our full length antibody with a new radio-immunotherapy approach, (3) helping MabVax to evaluate additional CA19-9 expressing cancers for which our antibody development program may have utility beyond our current focus on pancreatic cancer, and (4) completing investigations supporting our radio-immunotherapy product for which we plan to submit an Investigational New Drug Application later this year."

Related Links:
Memorial Sloan Kettering Cancer Center
MabVax Therapeutics

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Wound Irrigation Solution
Prontosan®
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.